ES542829A0 - Un metodo para evitar la formacion de un enlace de disulfuro en una proteina. - Google Patents

Un metodo para evitar la formacion de un enlace de disulfuro en una proteina.

Info

Publication number
ES542829A0
ES542829A0 ES542829A ES542829A ES542829A0 ES 542829 A0 ES542829 A0 ES 542829A0 ES 542829 A ES542829 A ES 542829A ES 542829 A ES542829 A ES 542829A ES 542829 A0 ES542829 A0 ES 542829A0
Authority
ES
Spain
Prior art keywords
protein
avoid
formation
interleukin
muteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES542829A
Other languages
English (en)
Other versions
ES8608043A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27030446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES542829(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of ES8608043A1 publication Critical patent/ES8608043A1/es
Publication of ES542829A0 publication Critical patent/ES542829A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES542829A 1982-10-19 1985-05-03 Un metodo para evitar la formacion de un enlace de disulfuro en una proteina. Expired ES8608043A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43515482A 1982-10-19 1982-10-19
US48616283A 1983-04-15 1983-04-15

Publications (2)

Publication Number Publication Date
ES8608043A1 ES8608043A1 (es) 1986-06-01
ES542829A0 true ES542829A0 (es) 1986-06-01

Family

ID=27030446

Family Applications (4)

Application Number Title Priority Date Filing Date
ES526541A Granted ES526541A0 (es) 1982-10-19 1983-10-18 Un procedimiento para preparar una muteina sintetica de una proteina biologicamente activa
ES533054A Expired ES8506801A1 (es) 1982-10-19 1984-06-01 Un metodo para producir un gen que contiene una muteina sintetica de una proteina biologicamente activa
ES533053A Granted ES533053A0 (es) 1982-10-19 1984-06-01 Un procedimiento para preparar una celula u organismo recombinante
ES542829A Expired ES8608043A1 (es) 1982-10-19 1985-05-03 Un metodo para evitar la formacion de un enlace de disulfuro en una proteina.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES526541A Granted ES526541A0 (es) 1982-10-19 1983-10-18 Un procedimiento para preparar una muteina sintetica de una proteina biologicamente activa
ES533054A Expired ES8506801A1 (es) 1982-10-19 1984-06-01 Un metodo para producir un gen que contiene una muteina sintetica de una proteina biologicamente activa
ES533053A Granted ES533053A0 (es) 1982-10-19 1984-06-01 Un procedimiento para preparar una celula u organismo recombinante

Country Status (23)

Country Link
EP (4) EP0109748B1 (es)
JP (2) JPS6128392A (es)
KR (1) KR910009900B1 (es)
AT (4) ATE46539T1 (es)
AU (1) AU563962B2 (es)
BE (1) BE898016A (es)
CA (1) CA1340861C (es)
CH (1) CH669395A5 (es)
DE (4) DE3380598D1 (es)
DK (2) DK168767B1 (es)
ES (4) ES526541A0 (es)
FI (1) FI82266C (es)
FR (1) FR2534594B1 (es)
GB (1) GB2130219B (es)
GR (1) GR79408B (es)
IE (1) IE56026B1 (es)
IL (1) IL69970A (es)
LU (3) LU88761I2 (es)
NL (2) NL930119I2 (es)
NO (1) NO173740C (es)
NZ (1) NZ205922A (es)
PH (2) PH20343A (es)
PT (1) PT77512B (es)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
NZ208309A (en) * 1983-06-01 1988-04-29 Hoffmann La Roche Recombinant leukocyte, fibroblast, or immune interferons (rifn-#a#, b or #g#) with one cys residue replaced
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
JPS61500790A (ja) 1984-03-28 1986-04-24 シタス　コ−ポレイシヨン 微生物的に製造されたインターロイキン―２を含有する組成物
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
DE3574731D1 (de) * 1984-05-08 1990-01-18 Genetics Inst Ein menschlicher t-zellwachstumsfaktor.
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US5683688A (en) * 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
IL75318A (en) * 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
CA1275954C (en) 1984-08-31 1990-11-06 Hing Cheug Wong 3'-expression enhancing fragments and method
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
WO1986002068A1 (fr) * 1984-09-26 1986-04-10 Takeda Chemical Industries, Ltd. Separation mutuelle de proteines
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
US4857316A (en) * 1984-10-03 1989-08-15 Syntex (U.S.A.) Inc. Synergistic antiviral composition
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US5342614A (en) * 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
US6107465A (en) * 1984-12-21 2000-08-22 Otsuka Pharmaceutical Co., Ltd. IL-1β and derivatives thereof and drugs
DK172052B1 (da) * 1984-12-21 1997-09-29 Otsuka Pharma Co Ltd Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor
DE3500681A1 (de) * 1985-01-11 1986-07-17 Hoechst Ag, 6230 Frankfurt Verfahren zur isolierung und reinigung von lymphokinen
US4863849A (en) * 1985-07-18 1989-09-05 New York Medical College Automatable process for sequencing nucleotide
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
WO1989000198A1 (en) * 1987-07-07 1989-01-12 Biotechnology Research Associates, J.V. Recombinant fibroblast growth factors
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
AU595864B2 (en) * 1986-03-14 1990-04-12 Otsuka Pharmaceutical Co., Ltd. Il-1 alpha derivatives and drugs
DE3683910D1 (de) * 1986-09-05 1992-03-26 Cetus Corp Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
US4987070A (en) * 1987-03-04 1991-01-22 Suntory Limited Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins
JP2602968B2 (ja) * 1987-11-04 1997-04-23 カリフォルニア バイオテクノロジー インコーポレイテッド 肺胞の界面活性タンパク類
ES2154627T3 (es) * 1988-08-24 2001-04-16 American Cyanamid Co Estabilizacion de somatotropinas mediante la modificacion de restos de cisteina utilizando mutagenesis de localizacion dirigida o derivatizacion quimica.
US5079230A (en) * 1988-09-12 1992-01-07 Pitman-Moore, Inc. Stable bioactive somatotropins
CA2003886A1 (en) * 1988-12-16 1990-06-16 Anthony F. Purchio Cloning and expression of simian transforming growth factor-beta 1
AU620673B2 (en) * 1989-01-31 1992-02-20 Pharmacia & Upjohn Company Somatotropin analogs
EP0383599B1 (en) * 1989-02-17 1996-02-07 Merck & Co. Inc. Protein anti-cancer agent
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US6207798B1 (en) 1989-08-03 2001-03-27 Merck & Co., Inc. Modified PE40 toxin fusion proteins
US5173297A (en) * 1991-07-01 1992-12-22 Quest International Flavors & Food Ingredients Company Division Of Indopco, Inc. Bacteriocin from lactococcus lactis subspecies lactis
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
FR2671554A1 (fr) * 1991-01-11 1992-07-17 Clonatec Sa Peptides synthetiques derivant de l'antigene hbc du virus de l'hepatite b, leurs applications a la detection d'une infection par ce virus et a la vaccination contre l'hepatite b.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
US5814485A (en) * 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
DE19544167A1 (de) * 1995-11-17 1997-05-22 Schering Ag Verwendung von Interferon-ß zur Behandlung von Bronchialkarzinom bei Bestrahlungstherapie
AU6399996A (en) * 1996-06-19 1998-01-07 Chiron Corporation Bacterial production of interferon-beta using low levels of sodium and potassium ions
CN1100875C (zh) * 1998-03-06 2003-02-05 上海华晨生物技术研究所 新型重组人白细胞介素2的制备方法及其表达载体和工程菌
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
EP1935431A3 (en) 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US20030082138A1 (en) * 2001-09-18 2003-05-01 Chiron Corporation Methods for treating multiple sclerosis
KR100511749B1 (ko) * 2001-11-06 2005-09-02 선바이오(주) 변형된 인터페론-베타, 및 이의 화학적으로 변형된 배합체
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
MXPA05002594A (es) 2002-09-11 2005-05-27 Fresenius Kabi Gmbh Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
SI1694360T1 (sl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Uporaba antagonističnih anti-CD40 protiteles za zdravljenje avtoimunskih in vnetnih bolezni in zavrnitve transplantata organa
CA2557677A1 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
CN101659704A (zh) 2004-03-11 2010-03-03 弗雷泽纽斯卡比德国有限公司 通过还原氨基化制备的羟烷基淀粉和蛋白质的偶联物
CA2573113A1 (en) * 2004-07-26 2006-02-09 Enzon Pharmaceuticals, Inc. Optimized interferon-beta gene
GB0523282D0 (en) 2005-11-15 2005-12-21 Isis Innovation Methods using pores
GB2453377A (en) 2007-10-05 2009-04-08 Isis Innovation Transmembrane protein pores and molecular adapters therefore.
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
ATE548052T1 (de) 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
CN102245760A (zh) 2008-07-07 2011-11-16 牛津纳米孔技术有限公司 酶-孔构建体
CN102144037A (zh) 2008-07-07 2011-08-03 牛津纳米孔技术有限公司 检测碱基的孔
US9077937B2 (en) * 2008-11-06 2015-07-07 Alcatel Lucent Method and apparatus for fast channel change
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
US9222082B2 (en) 2009-01-30 2015-12-29 Oxford Nanopore Technologies Limited Hybridization linkers
WO2010086622A1 (en) 2009-01-30 2010-08-05 Oxford Nanopore Technologies Limited Adaptors for nucleic acid constructs in transmembrane sequencing
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
JP6169976B2 (ja) 2011-02-11 2017-07-26 オックスフォード ナノポール テクノロジーズ リミテッド 変異体細孔
MX347324B (es) 2011-03-11 2017-04-19 Assist Publique-Hôpitaux De Paris Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.
WO2013014451A1 (en) 2011-07-25 2013-01-31 Oxford Nanopore Technologies Limited Hairpin loop method for double strand polynucleotide sequencing using transmembrane pores
GB201119244D0 (en) 2011-11-08 2011-12-21 British American Tobacco Co Smoking article
KR102083695B1 (ko) 2012-04-10 2020-03-02 옥스포드 나노포어 테크놀로지즈 리미티드 돌연변이체 리세닌 기공
WO2014013259A1 (en) 2012-07-19 2014-01-23 Oxford Nanopore Technologies Limited Ssb method
SG11201507138RA (en) 2013-03-08 2015-10-29 Oxford Nanopore Tech Ltd Enzyme stalling method
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
US10183061B2 (en) 2013-06-25 2019-01-22 Icm (Institut Du Cerveau Et De La Moelle Epiniere) Boosting Treg cells for treating Alzheimer disease and related disorders
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
EP2918285A1 (en) 2014-03-11 2015-09-16 Université Pierre et Marie Curie (Paris 6) Interleukin-2 for treating food allergy
WO2015166275A1 (en) 2014-05-02 2015-11-05 Oxford Nanopore Technologies Limited Mutant pores
KR20170042794A (ko) 2014-09-01 2017-04-19 브이아이비 브이지더블유 돌연변이체 csgg 포어
US10266885B2 (en) 2014-10-07 2019-04-23 Oxford Nanopore Technologies Ltd. Mutant pores
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
US10801023B2 (en) * 2015-04-24 2020-10-13 University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in plants and libraries of plants expressing candidate biologically active random peptides
US10876109B2 (en) 2015-04-24 2020-12-29 University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in prokaryotic cells and libraries of prokaryotic cells expressing candidate biologically active random peptides
WO2016172445A2 (en) * 2015-04-24 2016-10-27 The University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in plants and libraries of plants expressing candidate biologically active random peptides
PL3364944T3 (pl) 2015-10-22 2025-02-24 Iltoo Pharma Kompozycje farmaceutyczne IL-2
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
ES2988783T3 (es) 2016-06-22 2024-11-21 David Klatzmann Linfocitos T genéticamente modificados
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019158764A1 (en) 2018-02-16 2019-08-22 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2020102556A1 (en) 2018-11-15 2020-05-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods of prognosis and classification for preeclampsia
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
CN115190885A (zh) 2019-12-12 2022-10-14 艾尔图制药公司 白细胞介素2嵌合构建体
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
US20230090069A1 (en) 2020-03-06 2023-03-23 Centre Hospitalier Universitaire De Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
CN115989239A (zh) * 2020-04-29 2023-04-18 瑷备恩有限公司 具有双重突变的人干扰素β变体和用于改善人干扰素β变体的稳定性的方法
WO2021221470A1 (ko) * 2020-04-29 2021-11-04 (주) 제노팜 인터페론-베타 변이체와 항체가 융합된 재조합 단백질 및 이를 포함하는 약학 조성물
IL300738A (en) * 2020-08-28 2023-04-01 Biocad Joint Stock Co A vaccine for SARS-COV-2 based on AAV5
MX2024004291A (es) 2021-10-06 2024-06-28 Iltoo Pharma Construcciones quiméricas de interleucina 2 con especificidad de direccionamiento a tejidos inflamados.
KR20240038789A (ko) * 2022-05-24 2024-03-25 제이에이치엠 바이오파마슈티컬 (항저우) 씨오., 엘티디. 재조합 보툴리눔 신경독소 a형 및 이의 제조 방법
CA3259108A1 (en) 2022-06-16 2023-12-21 Cephalon Llc Attenuated Anti-PD1-IL2 Immunoconjugates and Their Uses
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
WO2024121173A1 (en) 2022-12-05 2024-06-13 Centre Hospitalier Universitaire De Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5359688A (en) * 1976-11-11 1978-05-29 Tanpakushitsu Kenkiyuu Shiyour Production of novel polypeptide
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
NO811118L (no) * 1980-04-03 1981-10-05 Biogen Nv Dna-sekvenser, rekombinante dna-molekyler og fremgangsmaate ved fremstilling av polypeptider
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
NZ208309A (en) * 1983-06-01 1988-04-29 Hoffmann La Roche Recombinant leukocyte, fibroblast, or immune interferons (rifn-#a#, b or #g#) with one cys residue replaced
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins

Also Published As

Publication number Publication date
EP0192811B1 (en) 1991-03-06
KR910009900B1 (ko) 1991-12-03
NZ205922A (en) 1987-11-27
PH23702A (en) 1989-09-27
NL930119I1 (nl) 1993-11-01
DK171681B1 (da) 1997-03-10
EP0109748B1 (en) 1988-04-13
NL930119I2 (nl) 1995-01-16
CH669395A5 (es) 1989-03-15
GB2130219A (en) 1984-05-31
DE3382528D1 (de) 1992-04-16
IL69970A (en) 1991-05-12
AU2008683A (en) 1984-05-03
DE3380598D1 (en) 1989-10-26
ATE61407T1 (de) 1991-03-15
GB8327490D0 (en) 1983-11-16
JPS6420096A (en) 1989-01-24
EP0192811A1 (en) 1986-09-03
PT77512B (en) 1987-11-24
NO833793L (no) 1984-04-24
ES533054A0 (es) 1985-08-01
CA1340861C (en) 1999-12-28
NL960013I1 (nl) 1996-10-01
FI82266C (fi) 1991-02-11
GR79408B (es) 1984-10-22
DE3382197D1 (de) 1991-04-11
FI82266B (fi) 1990-10-31
FI833681L (fi) 1984-04-20
ES8608043A1 (es) 1986-06-01
LU90413I2 (fr) 1999-09-07
IL69970A0 (en) 1984-01-31
DK105892D0 (da) 1992-08-26
ES8505717A1 (es) 1985-04-01
NL960013I2 (nl) 1997-03-03
ATE46539T1 (de) 1989-10-15
GB2130219B (en) 1986-01-29
EP0218825A1 (en) 1987-04-22
ATE33503T1 (de) 1988-04-15
ES526541A0 (es) 1985-04-01
DK105892A (da) 1992-08-26
BE898016A (fr) 1984-02-15
FI833681A0 (fi) 1983-10-10
PH20343A (en) 1986-12-04
DK481383D0 (da) 1983-10-19
ES8506089A1 (es) 1985-06-16
ATE73493T1 (de) 1992-03-15
EP0109748A1 (en) 1984-05-30
JPS6128392A (ja) 1986-02-08
DE3376271D1 (en) 1988-05-19
LU88357I2 (fr) 1994-05-04
NO173740B (no) 1993-10-18
IE56026B1 (en) 1991-03-27
EP0218825B1 (en) 1989-09-20
EP0234599A1 (en) 1987-09-02
FR2534594B1 (fr) 1987-06-19
JPH0568480B2 (es) 1993-09-29
ES8506801A1 (es) 1985-08-01
EP0234599B1 (en) 1992-03-11
IE832380L (en) 1984-04-19
PT77512A (en) 1983-11-01
DK168767B1 (da) 1994-06-06
FR2534594A1 (fr) 1984-04-20
KR840006369A (ko) 1984-11-29
AU563962B2 (en) 1987-07-30
NO173740C (no) 1994-01-26
DK481383A (da) 1984-04-20
LU88761I2 (fr) 1996-11-05
ES533053A0 (es) 1985-06-16

Similar Documents

Publication Publication Date Title
ES542829A0 (es) Un metodo para evitar la formacion de un enlace de disulfuro en una proteina.
DK0402300T3 (da) Fremstilling i bakterier af gær og hæmoglobin og analoger dertil
PT97160A (pt) Processo para a preparacao de composicoes estaveis para administracao parenterica contendo uma proteina, peptideo ou polipeptideo biologicamente activo
DE3486263D1 (de) Intraokulares Linsenimplantat.
SE8103594L (sv) N-(vinblastin-23-oyl)aminosyraderivat
ES2073081T3 (es) Proteinas de fusion a base de interleucina-2 e hirudina.
DE3687763D1 (de) Oxidationsbestaendige il-2-muteine und ihre herstellung, diese muteine enthaltende zusammensetzungen, solche muteine kodierende dns-sequenzen und expressionsvektoren und korrespondierende transformierte wirtzellen.
ES2033678T3 (es) Procedimiento para la preparacion de una proteina de fusion.
DK403384D0 (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
PT93178A (pt) Agente proteico anticanceroso

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20060110